Bleichroeder LP Cassava Sciences Inc Transaction History

Bleichroeder LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 11, 2022	SELL	$32.6 - $53.05 $244,500 - $397,875	-7,500 Reduced 60.0%	5,000 $186,000
Q4 2021 Feb 10, 2022	BUY	$36.77 - $90.91 $459,625 - $1.14 Million	12,500 New	12,500 $546,000
Q3 2021 Nov 15, 2021	SELL	$41.79 - $135.3 $15.7 Million - $50.7 Million	-375,000 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$32.15 - $89.72 $4.02 Million - $11.2 Million	-125,000 Reduced 25.0%	375,000 $32 Million
Q1 2021 May 17, 2021	BUY	$7.09 - $87.95 $1.53 Million - $19 Million	215,686 Added 75.86%	500,000 $22.5 Million
Q4 2020 Feb 10, 2021	SELL	$6.79 - $12.25 $2.72 Million - $4.9 Million	-400,189 Reduced 58.46%	284,314 $1.94 Million
Q3 2020 Nov 12, 2020	SELL	$2.86 - $11.51 $1.05 Million - $4.21 Million	-366,000 Reduced 34.84%	684,503 $7.88 Million
Q2 2020 Aug 12, 2020	BUY	$2.04 - $9.64 $2.13 Million - $10.1 Million	1,043,353 Added 14592.35%	1,050,503 $3.24 Million
Q1 2020 May 14, 2020	SELL	$3.26 - $9.65 $5.65 Million - $16.7 Million	-1,732,390 Reduced 99.59%	7,150 $29,000
Q4 2019 Feb 14, 2020	BUY	$1.1 - $6.12 $1.91 Million - $10.6 Million	1,739,540 New	1,739,540 $9.05 Million

207

14M

2.98M

6.57M

Ticker SAVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,097,900
Market Cap $94.2M
Description
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...

Get notified when there are updates to the investment portfolio of Bleichroeder LP, based on Form 13F filings with the SEC.

Stay updated on Bleichroeder LP with notifications on news.